Skip to content
  • About us
    • Advisory Board
    • Our mission
    • GDPR Policy
  • Editorial guidelines
    • Peer-review protocol
    • Author guidelines
    • Editorial Calendar 2018
    • Editorial Calendar 2017
  • Advertise with us
    • Media Information 2021
    • Media Information 2020
  • Subscribe
    • weekly newsletter
  • Contact Us
secondary menu
Journal for Clinical Studies
Journal for Clinical StudiesJournal for Clinical Studies
 

 

  • Home
  • Current features/ Volume 13 Issue 1
  • Editorial Archive
    • Volume 12 Issue 6
    • Volume 12 Issue 5
    • Volume 12 Issue 4
    • Volume 12 Issue 3
    • Volume 12 Issue 2
    • Volume 12 Issue 1
    • Volume 11 Issue 6
    • Volume 11 Issue 5
    • Volume 11 Issue 4
    • Volume 11 Issue 3
    • Volume 11 Issue 2
    • Volume 11 Issue 1
    • Volume 10 Issue 6
    • Volume 10 Issue 5
    • Volume 10 Issue 4
    • Volume 10 Issue 3
    • Volume 10 Issue 2
    • Volume 10 Issue 1
    • Volume 9 Issue 6
      • Volume 10 Issue 6
    • Volume 9 Issue 5
    • Volume 9 Issue 4
    • Volume 9 Issue 3
    • Volume 9 Issue 2
    • Volume 9 Issue 1
      • Regulatory V9 I1
      • Market Report V9 I1
      • Therapeutics V9 I1
      • IT & Logistics V9 I1
    • Volume 8 Issue 6
      • Watch Pages
      • Regulatory
      • Market Report
      • Technology
      • Therapeutics
      • Special Features
      • Logistics
    • Volume 8 Issue 5
      • Watch Pages V8 I5
      • Regulatory V8 I5
      • Market Report V8 I5
      • Technology V8 I5
      • Therapeutics V8 I5
      • Special Features V8 I5
      • Logistics V8 I5
    • Volume 8 Issue 4
      • Watch Pages V8 I4
      • Regulatory V8 I4
      • Market Report V8 I4
      • Therapeutics V8 I4
      • Technology V8 I4
      • Logistics V8 I4
      • Special Feature V8 I4
    • Volume 8 Issue 3
      • Watch Pages V8 I3
      • Regulatory V8 I3
      • Market Report V8 I3
      • Therapeutics V8 I3
      • Technology V8 I3
      • Logistics V8 I3
      • Special Feature V8 I3
    • Volume 8 Issue 2
      • Watch Pages
      • Regulatory
      • Market Report
      • Therapeutics
      • IT & Logistics
      • Special Features
    • Volume 8 Issue 1
    • Volumen 8 Issue 1
      • Watch Pages
      • Regulatory
      • Market Report
      • Therapeutics
      • IT & Logistics
      • Special Features
    • Volume 7 Issue 6
      • Watch Pages
      • Regulatory
      • Market Report
      • Therapeutics
      • IT & Logistics
      • Special Features
    • Volume 7 Issue 5
      • Watch Pages
      • Regulatory
      • Market Report
      • Therapeutics
      • IT & Logistics
      • Special Features
    • Volume 7 Issue 4
      • Watch Pages
      • Regulatory
      • Market Report
      • Therapeutics
      • IT & Logistics
      • Special Features
    • Volume 7 issue 3
      • Watch Pages
      • Therapeutics
      • Research & Development
      • Regulatory & Marketplace
      • IT & Logistics
      • Special Features
    • Volume 7 Issue 2
      • Watch Pages
      • Regulatory
      • Market Report
      • Therapeutics
      • Technology
      • Logistics
    • Volume 7 Issue 1
      • Watch Pages
      • Regulatory
      • Market Report
      • Therapeutics
      • Technology
      • Logistics
    • Volume 6 Issue 6
      • Watch Pages
      • Regulatory
      • Market Report
      • Therapeutics
      • IT & Logistics
    • Volume 6 Issue 5
      • Watch Pages
      • Regulatory
      • Market Report
      • Therapeutics
      • IT & Logistics
    • Volume 6 Issue 4
      • Watch Pages
      • Regulatory
      • Market Report
      • Therapeutics
      • IT & Logistics
    • Volume 6 Issue 3
      • Watch Pages
      • Regulatory
      • Market Report
      • Therapeutics
      • IT & Logistics
    • Volume 6 Issue 2
      • Watch Pages
      • Regulatory
      • Market Report
      • Therapeutics
      • It & Logistics
      • Special Features
    • Volume 6 Issue 1
      • Watch Pages
      • Regulatory
      • Market Report
      • Therapeutics
      • IT & Logistics
    • Volume 5 Issue 6
      • Watch Pages
      • Regulatory
      • Market Report
      • It & Logistics
      • Therapeutics
      • Special Features
    • Volume 5 Issue 5
      • Watch Pages
      • Regulatory
      • Market Report
      • Therapeutics
      • IT & Logistics
      • Special Features
    • Volume 5 Issue 4
      • Watch Pages
      • Regulatory
      • Market Report
      • Therapeutics
      • IT & Logistics
      • Special Feature
    • Volume 5 Issue 3
      • Watch Pages
      • Regulatory
      • Market Report
      • Therapeutics
      • IT & Logistics
  • Archived Issues
  • Industry events
  • Company Profile
    • A-D
    • E-M
    • N-S
    • T-Z
  • Regional News
    • Asia Pacific
    • Australasia
    • Europe
    • Latin America
    • MEANA Region
    • North America
    • Russia/Eastern Europe
    • Scandinavia
    • South Africa
    • Sub Saharan Africa
  • eBooks
  • Podcast
  • Home
  • Current features/ Volume 13 Issue 1
  • Editorial Archive
    • Volume 12 Issue 6
    • Volume 12 Issue 5
    • Volume 12 Issue 4
    • Volume 12 Issue 3
    • Volume 12 Issue 2
    • Volume 12 Issue 1
    • Volume 11 Issue 6
    • Volume 11 Issue 5
    • Volume 11 Issue 4
    • Volume 11 Issue 3
    • Volume 11 Issue 2
    • Volume 11 Issue 1
    • Volume 10 Issue 6
    • Volume 10 Issue 5
    • Volume 10 Issue 4
    • Volume 10 Issue 3
    • Volume 10 Issue 2
    • Volume 10 Issue 1
    • Volume 9 Issue 6
      • Volume 10 Issue 6
    • Volume 9 Issue 5
    • Volume 9 Issue 4
    • Volume 9 Issue 3
    • Volume 9 Issue 2
    • Volume 9 Issue 1
      • Regulatory V9 I1
      • Market Report V9 I1
      • Therapeutics V9 I1
      • IT & Logistics V9 I1
    • Volume 8 Issue 6
      • Watch Pages
      • Regulatory
      • Market Report
      • Technology
      • Therapeutics
      • Special Features
      • Logistics
    • Volume 8 Issue 5
      • Watch Pages V8 I5
      • Regulatory V8 I5
      • Market Report V8 I5
      • Technology V8 I5
      • Therapeutics V8 I5
      • Special Features V8 I5
      • Logistics V8 I5
    • Volume 8 Issue 4
      • Watch Pages V8 I4
      • Regulatory V8 I4
      • Market Report V8 I4
      • Therapeutics V8 I4
      • Technology V8 I4
      • Logistics V8 I4
      • Special Feature V8 I4
    • Volume 8 Issue 3
      • Watch Pages V8 I3
      • Regulatory V8 I3
      • Market Report V8 I3
      • Therapeutics V8 I3
      • Technology V8 I3
      • Logistics V8 I3
      • Special Feature V8 I3
    • Volume 8 Issue 2
      • Watch Pages
      • Regulatory
      • Market Report
      • Therapeutics
      • IT & Logistics
      • Special Features
    • Volume 8 Issue 1
    • Volumen 8 Issue 1
      • Watch Pages
      • Regulatory
      • Market Report
      • Therapeutics
      • IT & Logistics
      • Special Features
    • Volume 7 Issue 6
      • Watch Pages
      • Regulatory
      • Market Report
      • Therapeutics
      • IT & Logistics
      • Special Features
    • Volume 7 Issue 5
      • Watch Pages
      • Regulatory
      • Market Report
      • Therapeutics
      • IT & Logistics
      • Special Features
    • Volume 7 Issue 4
      • Watch Pages
      • Regulatory
      • Market Report
      • Therapeutics
      • IT & Logistics
      • Special Features
    • Volume 7 issue 3
      • Watch Pages
      • Therapeutics
      • Research & Development
      • Regulatory & Marketplace
      • IT & Logistics
      • Special Features
    • Volume 7 Issue 2
      • Watch Pages
      • Regulatory
      • Market Report
      • Therapeutics
      • Technology
      • Logistics
    • Volume 7 Issue 1
      • Watch Pages
      • Regulatory
      • Market Report
      • Therapeutics
      • Technology
      • Logistics
    • Volume 6 Issue 6
      • Watch Pages
      • Regulatory
      • Market Report
      • Therapeutics
      • IT & Logistics
    • Volume 6 Issue 5
      • Watch Pages
      • Regulatory
      • Market Report
      • Therapeutics
      • IT & Logistics
    • Volume 6 Issue 4
      • Watch Pages
      • Regulatory
      • Market Report
      • Therapeutics
      • IT & Logistics
    • Volume 6 Issue 3
      • Watch Pages
      • Regulatory
      • Market Report
      • Therapeutics
      • IT & Logistics
    • Volume 6 Issue 2
      • Watch Pages
      • Regulatory
      • Market Report
      • Therapeutics
      • It & Logistics
      • Special Features
    • Volume 6 Issue 1
      • Watch Pages
      • Regulatory
      • Market Report
      • Therapeutics
      • IT & Logistics
    • Volume 5 Issue 6
      • Watch Pages
      • Regulatory
      • Market Report
      • It & Logistics
      • Therapeutics
      • Special Features
    • Volume 5 Issue 5
      • Watch Pages
      • Regulatory
      • Market Report
      • Therapeutics
      • IT & Logistics
      • Special Features
    • Volume 5 Issue 4
      • Watch Pages
      • Regulatory
      • Market Report
      • Therapeutics
      • IT & Logistics
      • Special Feature
    • Volume 5 Issue 3
      • Watch Pages
      • Regulatory
      • Market Report
      • Therapeutics
      • IT & Logistics
  • Archived Issues
  • Industry events
  • Company Profile
    • A-D
    • E-M
    • N-S
    • T-Z
  • Regional News
    • Asia Pacific
    • Australasia
    • Europe
    • Latin America
    • MEANA Region
    • North America
    • Russia/Eastern Europe
    • Scandinavia
    • South Africa
    • Sub Saharan Africa
  • eBooks
  • Podcast

Tag Archives: study

New Nature Medicine Study Demonstrates Ability of The Guardant360 Assay to Predict Patient Response to Immunotherapy in Advanced Gastric Cancer Patients

EuropeBy flabio525th July 2018

Researchers from Samsung Medical Center and Guardant Health, Inc. have demonstrated the feasibility of determining a measure analogous to tumor…

Study: Brain Exercise Improves Brain Function in Retirement Community Population

EuropeBy flabio518th July 2018

A newly published study of older adults residing in assisted living and independent living communities shows significant improvement in brain processing speed…

After failure, Zynerba shifts gears to save cash

EuropeBy flabio511th July 2018

Zynerba Pharmaceuticals on Thursday announced negative topline results from a Phase 1 safety and dosing study of its transdermal tetrahydrocannabinol…

Novo’s oral semaglutide outperforms Jardiance in late-stage study

EuropeBy flabio56th June 2018

Danish drugmaker Novo Nordisk said Tuesday its PIONEER 2 study testing oral semaglutide in patients with type 2 diabetes met…

AstraZeneca won’t submit lung drug for COPD after 2nd study miss

EuropeBy flabio56th June 2018

AstraZeneca no longer plans to seek approval of its new respiratory biologic Fasenra in chronic obstructive pulmonary disease (COPD) after the…

Madrigal scores in mid-stage NASH study

EuropeBy flabio56th June 2018

Madrigal Pharmaceuticals on Thursday reported highly anticipated results for its Phase 2 non-alcoholic steatohepatitis (NASH) drug MGL-3196, unveiling positive data…

Ultragenyx and Kyowa Kirin Announce Publication of Phase 2 Study Results Demonstrating that Crysvita® (burosumab) Improved Outcomes in Children with X-linked Hypophosphatemia in the New England Journal of Medicine

EuropeBy flabio531st May 2018

Pediatric Study Demonstrated Improvements in Rickets Severity, Growth, Pain and Physical Activity in Children with Debilitating, Lifelong Hereditary Disease Ultragenyx…

Genmab Announces Topline Results in Phase III study of Arzerra® in Indolent Non-Hodgkin’s Lymphoma

EuropeBy flabio531st May 2018

Topline results from Phase III study in iNHL did not meet primary endpoint of improved progression-free survival Genmab A/S (Nasdaq…

Rapid Medical initiates TIGER Clinical Study

North AmericaBy flabio523rd May 2018

Data from the study will be submitted to the FDA in support of Market Clearance for TIGERTRIEVER in the U.S.…

Ultragenyx and Kyowa Kirin Announce Topline Phase 3 Study Results Demonstrating Superiority of Crysvita® (burosumab) Treatment to Oral Phosphate and Active Vitamin D in Children with X-Linked Hypophosphatemia (XLH)

Asia Pacific, Europe, North AmericaBy flabio523rd May 2018

Substantial Healing of Rickets Observed in 72% of Patients Treated with Crysvita Compared to 6% of Patients Receiving Conventional Therapy…

123
© 2020 Jforcs Media, All Rights Reserved. Powered by Teksyte LTD
Go to Top